Thursday, April 3, 2025
4/3/2025
Photothermal Nanoparticles Immune Engineer Tumor-specific T cells for Adoptive Cell Therapy - PROJECT SUMMARY This goal of this proposal is to investigate a novel photothermal nanoparticle-based approach for generating tumor-specific T cells as an adoptive T cell therapy (ATCT) for glioblastoma (GBM). Despite being the most commonly diagnosed brain tumor, the prognosis for GBM patients is dismal, with a relative five-year survival rate of 7.5%. Hence, there is an urgent need for novel therapies for this patient population. In response, we are synthesizing novel Prussian blue nanoparticle-based formulations that will be used to administer photothermal therapy (PBNP-PTT) and generate a personalized ATCT for GBM. Our approach involves treating GBM tumor cells resected during surgery with PBNP-PTT ex vivo, and co-culturing them with dendritic cells (DCs) and T cells expanded from PBMCs sourced from the patient or a matched donor, to expand GBM-specific T cells for subsequent ATCT. We envision our therapy to be administered to patients after standard-of-care regimens of surgery, chemotherapy, and radiation therapy, when GBM patients are in a minimally residual disease state, with the goal of maximizing the impact of the T cell therapy thus improving survival outcomes. In a recently published study with GBM tumor cell lines, we demonstrated that PBNP-PTT generated more potent tumor-specific T cells in terms of specificity and cytolytic function, when compared to T cells generated by freeze-thaw lysis of the GBM tumor cells or by heating of the tumor cells on a heat block at equivalent thermal doses. In vivo, our immune engineered T cells eliminated orthotopically implanted U87 xenograft tumors and significantly improved survival compared to tumor-bearing animals treated with lysate-derived, antigen (PRAME)-specific, or PHA-expanded T cells, and control treatments. Operationally, our approach represents a more seamless workflow than other personalized approaches. It involves a straightforward, single administration of PBNP-PTT to the GBM cells isolated after surgery for 10 minutes using PBNPs pre-synthesized with GLP techniques and a portable laser, followed by well-established DC and T cell expansion protocols. Building on these promising findings, we now propose to synthesize multiple PBNP-PTT nanoformulations to generate and expand tumor-specific T cells and conduct studies testing their efficacy in vitro, in vivo, and ex vivo, as well as mechanistic studies. We hypothesize that PBNP-PTT of GBM tumor cells using our PBNP nanoformulations significantly enhances antigen release and capture by the PBNPs, their processing and presentation by DCs allowing more robust activation of a diverse T cell population, which subsequently differentiates into cytotoxic effector and long-lasting memory phenotypes, the ideal ATCT product for safe and effective treatment of GBM. Success in this project will demonstrate the use of PBNP-PTT nanoformulations to generate a transformative, new class of ATCT for GBM.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).